Antileukemic effect of high-dose thymidine in rat model for acute myeloid leukemia (BNML)
article
The efficacy of high-dose thymidine (HD-TdR) was investigated as a function of various routes and schedules of administration in a rat model for acute myelocytic leukemia (BNML). The drug was administered either intravenously (i.e.) or intraperitoneally (i.p.) or by continuous infusion (c.i.) at different intervals. Five-day treatment with HD-TdR at a daily dosage of 20-40 g/m2 did not lead to an increase in survival when compared with saline-treated controls. Among the investigated regimens c.i. led either to a significant reduction of survival or death during treatment. As can be derived from assays for the estimation of clonogenic bone marrow cells (CFU-S). HD-TdR treatment during a 5-day period is strongly toxic to the haemopoietic organ. It can be concluded that the lack of efficacy of HD-TdR in acute myeloid leukemia is due to haematotoxicity.
Topics
antileukemic agentcyclophosphamidecytarabinedaunorubicindoxorubicinthymidinetioguaninevincristineacute myeloblastic leukemiaanimal experimentbiological modelblood and hemopoietic systemcancer chemotherapymodelratAnimalColony-Forming Units AssayDose-Response Relationship, DrugFemaleInjections, IntraperitonealInjections, IntravenousLeukemia, ExperimentalLeukemia, Myelocytic, AcuteRatsSupport, Non-U.S. Gov'tThymidine
TNO Identifier
229033
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 17(1), pp. 89-92.
Pages
89-92
Files
To receive the publication files, please send an e-mail request to TNO Repository.